C Stefanutti1, D J Blom2, M R Averna3, E A Meagher4, H dT Theron5, A D Marais2, R A Hegele6, C R Sirtori7, P K Shah8, D Gaudet9, G B Vigna10, B S Sachais4, S Di Giacomo1, A M E du Plessis11, L T Bloedon12, J Balser13, D J Rader4, M Cuchel14. 1. 'Sapienza' University of Rome, Rome, Italy. 2. University of Cape Town, Cape Town, South Africa. 3. Università di Palermo, Palermo, Italy. 4. University of Pennsylvania, Philadelphia, PA, USA. 5. Netcare Private Hospital, Bloemfontein, South Africa. 6. Robarts Research Institute and University of Western Ontario, London, ON, Canada. 7. Ospedale Niguarda, Milano, Italy. 8. Cedars-Sinai Heart Institute, Los Angeles, CA, USA. 9. Université de Montreal, Chicoutimi, Canada. 10. Università di Ferrara, Ferrara, Italy. 11. University of Pretoria, South Africa. 12. Aegerion Pharmaceuticals, Cambridge, MA, USA. 13. Veristat, Holliston, MA, USA. 14. University of Pennsylvania, Philadelphia, PA, USA. Electronic address: mcuchel@mail.med.upenn.edu.
Abstract
OBJECTIVE: Lomitapide (a microsomal triglyceride transfer protein inhibitor) is an adjunctive treatment for homozygous familial hypercholesterolaemia (HoFH), a rare genetic condition characterised by elevated low-density lipoprotein-cholesterol (LDL-C), and premature, severe, accelerated atherosclerosis. Standard of care for HoFH includes lipid-lowering drugs and lipoprotein apheresis. We conducted a post-hoc analysis using data from a Phase 3 study to assess whether concomitant apheresis affected the lipid-lowering efficacy of lomitapide. METHODS: Existing lipid-lowering therapy, including apheresis, was to remain stable from Week -6 to Week 26. Lomitapide dose was escalated on the basis of individual safety/tolerability from 5 mg to 60 mg a day (maximum). The primary endpoint was mean percent change in LDL-C from baseline to Week 26 (efficacy phase), after which patients remained on lomitapide through Week 78 for safety assessment and further evaluation of efficacy. During this latter period, apheresis could be adjusted. We analysed the impact of apheresis on LDL-C reductions in patients receiving lomitapide. RESULTS: Of the 29 patients that entered the efficacy phase, 18 (62%) were receiving apheresis at baseline. Twenty-three patients (13 receiving apheresis) completed the Week 26 evaluation. Of the six patients who discontinued in the first 26 weeks, five were receiving apheresis. There were no significant differences in percent change from baseline of LDL-C at Week 26 in patients treated (-48%) and not treated (-55%) with apheresis (p = 0.545). Changes in Lp(a) levels were modest and not different between groups (p = 0.436). CONCLUSION: The LDL-C lowering efficacy of lomitapide is unaffected by lipoprotein apheresis.
OBJECTIVE:Lomitapide (a microsomal triglyceride transfer protein inhibitor) is an adjunctive treatment for homozygous familial hypercholesterolaemia (HoFH), a rare genetic condition characterised by elevated low-density lipoprotein-cholesterol (LDL-C), and premature, severe, accelerated atherosclerosis. Standard of care for HoFH includes lipid-lowering drugs and lipoprotein apheresis. We conducted a post-hoc analysis using data from a Phase 3 study to assess whether concomitant apheresis affected the lipid-lowering efficacy of lomitapide. METHODS: Existing lipid-lowering therapy, including apheresis, was to remain stable from Week -6 to Week 26. Lomitapide dose was escalated on the basis of individual safety/tolerability from 5 mg to 60 mg a day (maximum). The primary endpoint was mean percent change in LDL-C from baseline to Week 26 (efficacy phase), after which patients remained on lomitapide through Week 78 for safety assessment and further evaluation of efficacy. During this latter period, apheresis could be adjusted. We analysed the impact of apheresis on LDL-C reductions in patients receiving lomitapide. RESULTS: Of the 29 patients that entered the efficacy phase, 18 (62%) were receiving apheresis at baseline. Twenty-three patients (13 receiving apheresis) completed the Week 26 evaluation. Of the six patients who discontinued in the first 26 weeks, five were receiving apheresis. There were no significant differences in percent change from baseline of LDL-C at Week 26 in patients treated (-48%) and not treated (-55%) with apheresis (p = 0.545). Changes in Lp(a) levels were modest and not different between groups (p = 0.436). CONCLUSION: The LDL-C lowering efficacy of lomitapide is unaffected by lipoprotein apheresis.
Authors: Gilbert R Thompson; M Barbir; D Davies; P Dobral; M Gesinde; M Livingston; P Mandry; A D Marais; S Matthews; C Neuwirth; A Pottle; C le Roux; D Scullard; C Tyler; S Watkins Journal: Atherosclerosis Date: 2009-06-18 Impact factor: 5.162
Authors: Terry A Jacobson; Matthew K Ito; Kevin C Maki; Carl E Orringer; Harold E Bays; Peter H Jones; James M McKenney; Scott M Grundy; Edward A Gill; Robert A Wild; Don P Wilson; W Virgil Brown Journal: J Clin Lipidol Date: 2014-07-15 Impact factor: 4.766
Authors: Gerald F Watts; Samuel Gidding; Anthony S Wierzbicki; Peter P Toth; Rodrigo Alonso; W Virgil Brown; Eric Bruckert; Joep Defesche; Khoo Kah Lin; Michael Livingston; Pedro Mata; Klaus G Parhofer; Frederick J Raal; Raul D Santos; Eric J G Sijbrands; William G Simpson; David R Sullivan; Andrey V Susekov; Brian Tomlinson; Albert Wiegman; Shizuya Yamashita; John J P Kastelein Journal: Int J Cardiol Date: 2013-11-20 Impact factor: 4.164
Authors: S Moorjani; M Roy; C Gagné; J Davignon; D Brun; M Toussaint; M Lambert; L Campeau; S Blaichman; P Lupien Journal: Arteriosclerosis Date: 1989 Mar-Apr
Authors: Marina Cuchel; Emma A Meagher; Hendrik du Toit Theron; Dirk J Blom; A David Marais; Robert A Hegele; Maurizio R Averna; Cesare R Sirtori; Prediman K Shah; Daniel Gaudet; Claudia Stefanutti; Giovanni B Vigna; Anna M E Du Plessis; Kathleen J Propert; William J Sasiela; LeAnne T Bloedon; Daniel J Rader Journal: Lancet Date: 2012-11-02 Impact factor: 79.321
Authors: Børge G Nordestgaard; M John Chapman; Steve E Humphries; Henry N Ginsberg; Luis Masana; Olivier S Descamps; Olov Wiklund; Robert A Hegele; Frederick J Raal; Joep C Defesche; Albert Wiegman; Raul D Santos; Gerald F Watts; Klaus G Parhofer; G Kees Hovingh; Petri T Kovanen; Catherine Boileau; Maurizio Averna; Jan Borén; Eric Bruckert; Alberico L Catapano; Jan Albert Kuivenhoven; Päivi Pajukanta; Kausik Ray; Anton F H Stalenhoef; Erik Stroes; Marja-Riitta Taskinen; Anne Tybjærg-Hansen Journal: Eur Heart J Date: 2013-08-15 Impact factor: 29.983
Authors: Albert Wiegman; Samuel S Gidding; Gerald F Watts; M John Chapman; Henry N Ginsberg; Marina Cuchel; Leiv Ose; Maurizio Averna; Catherine Boileau; Jan Borén; Eric Bruckert; Alberico L Catapano; Joep C Defesche; Olivier S Descamps; Robert A Hegele; G Kees Hovingh; Steve E Humphries; Petri T Kovanen; Jan Albert Kuivenhoven; Luis Masana; Børge G Nordestgaard; Päivi Pajukanta; Klaus G Parhofer; Frederick J Raal; Kausik K Ray; Raul D Santos; Anton F H Stalenhoef; Elisabeth Steinhagen-Thiessen; Erik S Stroes; Marja-Riitta Taskinen; Anne Tybjærg-Hansen; Olov Wiklund Journal: Eur Heart J Date: 2015-05-25 Impact factor: 29.983